GWPH News and Press, GW Pharmaceuticals Plc From 08/24/19

Some didn't think that  GW Pharmaceuticals   (NASDAQ: GWPH) would be able to successfully market the first FDA-approved drug made from the cannabis plant. They were wrong. Sales for GW's cannabidiol (CBD) drug Epidiolex have been fantastic. The tremendous launch of Epidiolex has enab...

England's National Institute for Health and Care Excellence (NICE), the advisor to the National Health Service (NHS) on costs and care quality, has issued draft guidance recommending against routine access to GW Pharmaceuticals' (NASDAQ: GWPH ) Epidyolex (cannabidiol) for the treatment of ...

August 14, 2019 FN Media Group Presents Potstocknews.com Market Commentary   New York, NY – August 14, 2019 – In February, the World Health Organization recommended that the United Nations remove pot and its key components from a list of highly-c...

August 13, 2019 Palm Beach, FL – August 13, 2019 — Since the U.S. approved the 2018 Farm Bill, consumer demand for CBD has been explosive.  So much so, 14% of Americans , or roughly one in seven  now use some form of CBD for anxiety, insomnia, arthritis, m...

The cannabis industry is quickly emerging. Driven by regulatory changes around the world, the industry is expected to grow to be worth tens of billions of dollars annually over the next few years. The biggest of these opportunities lies in the United States. In fact, by 2025, experts expe...

I have a confession: I don't like the market environment that we are in. I would much prefer to invest at a time when government bonds have 5% real yields, when the Shiller P/E ratio is at 10, and when businesses reinvest their profits instead of buying back stock, while borrowing to the hilt....

GWPH stock is moving up double-digits after GW Pharmaceuticals (NASDAQ:GWPH) reported a big jump in its cannabis-derived epilepsy drug, Epidiolex. The medicine uses CBD, and it is known to be an effective treatment for some types of epilepsy. Impressive Quarterly Numbers As everyone k...

Rhythm Pharmaceuticals (NASDAQ: RYTM ) +29%  on positive late-stage setmelanotide data . More news on: Rhythm Pharmaceuticals, Inc., Guardant Health, Inc., Weight Watchers International, Inc., Stocks on the move, Read more ...

Listen on the go! Subscribe to The Cannabis Investing Podcast on Libsyn , Spotify , Stitcher or Apple Podcasts . By Jonathan Liss Today I am very happy to welcome Dan Ahrens, manager of the recently launched AdvisorShares Pure Cannabis ETF ( YOLO ) to the ...

GW Pharmaceuticals plc (GWPH) Q2 2019 Earnings Conference Call August 6, 2019 4:30 PM ET Company Participants Stephen Schultz – Vice President-Investor Relations Justin Gover – Chief Executive Officer Darren Cline – U.S. Chief Commercial Officer Chris Tovey...